Hyperfine (HYPR) Debt to Equity (2020 - 2026)

Hyperfine (HYPR) reported Debt to Equity of $0.38 for Q1 2026, up 67175.02% quarter-over-quarter from $0.0 in Q1 2023.

Hyperfine (HYPR) Debt to Equity (2020 - 2026) Analysis & Trends

Hyperfine has reported Debt to Equity for 5 years, with the latest figure at $0.38 in Q1 2026.

For the quarter ending Q1 2026, Debt to Equity changed N/A year-over-year to $0.38; the trailing twelve-month figure through Mar 2026 stood at $0.38 (changed N/A YoY), and the FY2021 full-year result was $0.01, up 306.84% from the prior year.
Debt to Equity for Q1 2026 stood at $0.38, up from $0.0 in the prior quarter.
The five-year high for Debt to Equity was $0.38 in Q1 2026, with the low at $0.0 in Q3 2022.
Historically, Debt to Equity has averaged $0.08 across 3 years, with a median of $0.0 in 2023.
The largest YoY upside for Debt to Equity was 2.52% in 2023 against a maximum downside of 2.52% in 2023.
Hyperfine's Debt to Equity stood at $0.0 in 2022, then rose by 25.62% to $0.0 in 2023, then surged by 67175.02% to $0.38 in 2026.
The last three Debt to Equity figures came in at $0.38 (Q1 2026), $0.0 (Q1 2023), and $0.0 (Q3 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn	0.65
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn	0.64
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn	0.57
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn	0.42
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn	0.06
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn	0.95
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.71
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn	-
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn	0.27
10	Hyperfine	133.84 Mn	92.56 Mn	1.98 Mn	0.38

Download Data